EuroIntervention

EuroIntervention is the official peer-reviewed journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), published by Europa Digital & Publishing, founded in 2005, dedicated to percutaneous and surgical cardiovascular interventions, with a 2025 Journal Impact Factor of 9.2《欧洲介入》（EuroIntervention）是（EuroPCR）与欧洲经皮心血管介入协会（EAPCI）的官方同行评审期刊，由（Europa Digital & Publishing）出版，2005 年创刊，专注经皮与外科心血管介入，2025 年影响因子为 9.2。

Scope

• The journal aims to create a forum of high-quality research and education in the field of percutaneous and surgical cardiovascular interventions该刊旨在为经皮与外科心血管介入领域搭建高质量的研究与教育平台。
• It publishes original articles, state-of-the-art reviews, meta-analyses, consensus documents, trial design papers, research correspondences, editorials and viewpoints该刊发表原创论文、最新进展综述、荟萃分析、共识文件、试验设计论文、研究通信、社论与观点文章。
• While its foundation is clearly European, its outlook is international, and it is one of the few journals entirely dedicated to interventional cardiology该刊立足欧洲但视野国际化，是少数完全专注介入心脏病学的期刊之一。
• It welcomes the participation of surgeons and peripheral interventionalists alongside coronary and structural heart specialists该刊欢迎外科医生与外周介入医师，与冠脉及结构心脏病专家共同参与。
• Its online edition gives access to previously published issues, ahead-of-print articles and a wide range of moving images supplementing the printed edition其在线版提供往期内容、预出版文章，以及大量补充印刷版的动态影像。
• It is indexed in the Science Citation Index, Scopus and MEDLINE/PubMed该刊被（Science Citation Index）、（Scopus）与（MEDLINE/PubMed）收录。

History

• EuroIntervention kicked off in 2005, growing out of the merger of the Toulouse/Paris PCR course with the Rotterdam Euro CVS course at the start of the decade该刊于 2005 年创办，源自本世纪初图卢兹/巴黎（PCR）课程与鹿特丹（Euro CVS）课程的合并。
• Its first issue appeared in May 2005 during that year's EuroPCR, and in 2006 it was an early pioneer of a supplement on percutaneous valve interventions and structural heart disease其首期于 2005 年 5 月在当年的（EuroPCR）期间面世，并于 2006 年率先推出经皮瓣膜介入与结构心脏病专刊。
• Patrick W. Serruys was the founding editor-in-chief and led the journal for about two decades before becoming editor emeritus（Patrick W. Serruys）为首任主编，执掌该刊约二十年，此后转任荣休主编。
• It is published by Europa Digital & Publishing and released 24 times a year at regular intervals, with four of those issues also available in print该刊由（Europa Digital & Publishing）出版，每年定期出版 24 期，其中 4 期为纸质与线上同步。
• Its Journal Impact Factor rose from 6.534 in 2021 and 7.728 in 2022 to 9.5 in 2024 and 9.2 in 2025, holding a percentile rank of 91.4 in the first quartile其影响因子由 2021 年的 6.534 与 2022 年的 7.728 升至 2024 年的 9.5 与 2025 年的 9.2，稳居第一四分位、百分位排名 91.4。
• In the 2025 Scopus metrics the journal ranked first in interventional cardiology with a CiteScore of 13.0在 2025 年的（Scopus）指标中，该刊以 13.0 的引用分位居介入心脏病学第一。

Editors

• Davide Capodanno is the editor-in-chief, having taken over from the founding editor Patrick W. Serruys, who is now editor emeritus主编为（Davide Capodanno），其接任首任主编（Patrick W. Serruys），后者现为荣休主编。
• The deputy editors are Robert Byrne, Nieves Gonzalo, Michael Joner, Darren Mylotte and Frederik Zimmermann, with Franz-Josef Neumann as guest editor副编辑为（Robert Byrne）、（Nieves Gonzalo）、（Michael Joner）、（Darren Mylotte）与（Frederik Zimmermann），（Franz-Josef Neumann）任客座编辑。
• Sylvie Lhoste serves as the managing editor, and the editorial office handles submissions through the Editorial Manager system（Sylvie Lhoste）任执行编辑，编辑部通过（Editorial Manager）系统处理投稿。
• All content is peer reviewed and validated by an editorial board of renowned experts before publication所有内容在发表前均经同行评审，并由知名专家组成的编委会审核。^[1]
• The review process is single-blind, so reviewers see the names of the authors while their own identities are kept confidential评审采用单盲方式，审稿人可见作者姓名，而其自身身份对作者保密。
• After the editorial office checks the manuscript, the board decides whether to send it for peer review or reject it outright, and decisions are taken collegially, with typically one to three rounds of review编辑部先做形式审查，再由编委会决定送审或直接退稿，决定集体作出，通常经历一到三轮评审。
• If members of the board have a conflict of interest they take no part in the discussion, and authors may appeal a decision at the next editorial board meeting编委会成员若有利益冲突则不参与讨论，作者可在下一次编委会会议上对决定提出申诉。